Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FAYZ A HUDEFI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Addiction Medicine

NPI
1992740393
CMS profile
135740
Location
FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$241.28

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $241.28 6

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FAYZ A HUDEFI

NPI 1992740393 · CMS profile ID 135740

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Addiction Medicine

FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992740393?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992740393?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992740393?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1992740393?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $241.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neuronetics, Inc. $67.8311/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852777421 CMS
ITI, Inc. $118.7211/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830142643 CMS
Vanda Pharmaceuticals Inc. $12.9610/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838901757 CMS
Otsuka America Pharmaceutical, Inc. $13.5407/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834737879 CMS
Vanda Pharmaceuticals Inc. $12.7006/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838901755 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5303/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819983025 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $346.37 4
PY2020 $203.40 6
PY2021 $241.28 6
PY2023 $34.77 2
PY2024 $1,099.97 3
PY2025 $124.97 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,184,915.74 413
PY2024 Principal investigator $2,303,282.98 204
PY2023 Principal investigator $6,541,371.44 120
PY2022 Principal investigator $34,086.76 8
PY2021 Principal investigator $312,565.61 85
PY2020 Recipient $1,312.46 7
PY2020 Principal investigator $543,799.24 155
PY2019 Recipient $2,502.81 13
PY2019 Principal investigator $1,252,649.46 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

162 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $85.00 12/31/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171987
Principal investigator 1 Allergan, Inc. $496.41 12/31/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 721315487
Principal investigator 1 Allergan, Inc. $19,115.24 12/31/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment No dispute reported 06/30/2026 721315801
Principal investigator 1 Allergan, Inc. $690.30 12/31/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721316391
Principal investigator 1 Corcept Therapeutics $5,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568805
Principal investigator 1 Corcept Therapeutics $1,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568807
Principal investigator 1 Corcept Therapeutics $3,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568809
Principal investigator 1 Corcept Therapeutics $3,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568811
Principal investigator 1 Corcept Therapeutics $800.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568813
Principal investigator 1 Corcept Therapeutics $3,000.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568815
Principal investigator 1 Corcept Therapeutics $19.92 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568817
Principal investigator 1 Corcept Therapeutics $9,700.00 12/30/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-877 No dispute reported 06/30/2026 745568833
Principal investigator 1 Sage Therapeutics, Inc. $475.00 12/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749046261
Principal investigator 1 Sage Therapeutics, Inc. $900.00 12/17/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749046263
Principal investigator 1 Corcept Therapeutics $3,150.00 12/14/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568709
Principal investigator 1 Corcept Therapeutics $9.09 12/14/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568711
Principal investigator 1 Allergan, Inc. $400.00 12/10/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721311631
Principal investigator 1 Alkermes, Inc. $85.00 11/30/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171971
Principal investigator 1 Sage Therapeutics, Inc. $84,277.52 11/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749045759
Principal investigator 1 Sage Therapeutics, Inc. $1,380.00 11/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749045761
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 11/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749045763
Principal investigator 1 Sage Therapeutics, Inc. $32.50 11/19/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749045765
Principal investigator 1 Sage Therapeutics, Inc. $475.00 11/12/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749045653
Principal investigator 1 Allergan, Inc. $700.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 26-WEEK, MULTICENTER, OPEN-LABEL, FLEXIBLE-DOSE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF CARIPRAZINE IN THE TREATMENT OF PEDIATRIC PARTICIPANTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER No dispute reported 06/30/2026 721306575
Principal investigator 1 Alkermes, Inc. $85.00 10/31/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171969
Principal investigator 1 Allergan, Inc. $700.00 10/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
PIV PEDIATRIC BIPOLAR MANIA No dispute reported 06/30/2026 721305515
Principal investigator 1 Allergan, Inc. $327.00 10/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721305571
Principal investigator 1 Allergan, Inc. $169.00 10/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
PIV PEDIATRIC BIPOLAR MANIA No dispute reported 06/30/2026 721305691
Principal investigator 1 GW Research Limited $6,000.00 10/29/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH, LLC
GWAP19030 No dispute reported 06/30/2026 750016869
Principal investigator 1 Alkermes, Inc. $85.00 09/30/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171983
Principal investigator 1 Corcept Therapeutics $5,014.80 09/25/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568697
Principal investigator 1 Sage Therapeutics, Inc. $1,797.00 09/24/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044847
Principal investigator 1 Allergan, Inc. $500.00 09/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment No dispute reported 06/30/2026 721298577
Principal investigator 1 Allergan, Inc. $1,000.00 09/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment No dispute reported 06/30/2026 721298579
Principal investigator 1 Allergan, Inc. $7,000.00 09/18/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment No dispute reported 06/30/2026 721298581
Principal investigator 1 Allergan, Inc. $8,700.00 09/04/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 721295571
Principal investigator 1 Allergan, Inc. $700.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721295013
Principal investigator 1 Allergan, Inc. $700.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721295113
Principal investigator 1 GW Research Limited $12,500.00 08/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH, LLC
GWAP19030 No dispute reported 06/30/2026 750016877
Principal investigator 1 Corcept Therapeutics $10.22 08/14/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568695
Principal investigator 1 Allergan, Inc. $500.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 4-week, Multicenter, Randomized, Double-blind, Parallel-group, Plbo controlled Study of the Efficacy and Safety of Cariprazine in the Trtment of an Acute Manic Episode (with or without Mixed Features) Assoc with Bipolar I Disorder in Pediatric Pts 7-12 No dispute reported 06/30/2026 721289883
Principal investigator 1 GW Research Limited $5,500.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH, LLC
GWAP19030 No dispute reported 06/30/2026 750016873
Principal investigator 1 GW Research Limited $1,000.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH, LLC
GWAP19030 No dispute reported 06/30/2026 750016875
Principal investigator 1 Sage Therapeutics, Inc. $6,275.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044147
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044149
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044151
Principal investigator 1 Sage Therapeutics, Inc. $4,000.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044153
Principal investigator 1 Sage Therapeutics, Inc. $2,000.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044155
Principal investigator 1 Sage Therapeutics, Inc. $1,797.00 08/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) No dispute reported 06/30/2026 749044157
Principal investigator 1 Allergan, Inc. $8,200.00 08/12/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A 4-week, Multicenter, Randomized, Double-blind, Parallel-group, Plbo controlled Study of the Efficacy and Safety of Cariprazine in the Trtment of an Acute Manic Episode (with or without Mixed Features) Assoc with Bipolar I Disorder in Pediatric Pts 7-12 No dispute reported 06/30/2026 721289651
Principal investigator 1 Sage Therapeutics, Inc. $503.10 08/06/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749044025
Principal investigator 1 Allergan, Inc. $500.00 07/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721287317
Principal investigator 1 Allergan, Inc. $8,200.00 07/22/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THEPREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 721286319
Principal investigator 1 Alkermes, Inc. $85.00 07/15/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171975
Principal investigator 1 Corcept Therapeutics $1,768.00 07/07/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568691
Principal investigator 1 Corcept Therapeutics $5,738.40 07/07/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568693
Principal investigator 1 Corcept Therapeutics $393.90 06/29/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568681
Principal investigator 1 Corcept Therapeutics $9.16 06/29/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568683
Principal investigator 1 Corcept Therapeutics $10.03 06/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568679
Principal investigator 1 Alkermes, Inc. $85.00 06/14/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171965
Principal investigator 1 Alkermes, Inc. $85.00 05/15/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171961
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,500.00 05/13/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748383115
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,544.11 05/04/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748383015
Principal investigator 1 Corcept Therapeutics $20.00 05/04/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568677
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $40,272.00 04/29/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 748804709
Principal investigator 1 Sage Therapeutics, Inc. $750.00 04/29/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749042779
Principal investigator 1 Sage Therapeutics, Inc. $1,530.00 04/29/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 749042783
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $21,302.00 04/23/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole No dispute reported 06/30/2026 748804663
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $300.00 04/16/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 748804505
Principal investigator 1 Corcept Therapeutics $137.22 04/10/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568671
Principal investigator 1 Corcept Therapeutics $45.00 04/10/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568673
Principal investigator 1 Corcept Therapeutics $17,434.80 04/10/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568675
Principal investigator 1 Corcept Therapeutics $2,500.00 03/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568723
Principal investigator 1 Corcept Therapeutics $36.87 03/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568727
Principal investigator 1 Corcept Therapeutics $9.38 03/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568729
Principal investigator 1 Corcept Therapeutics $31.13 03/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568731
Principal investigator 1 Corcept Therapeutics $842.40 03/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568743
Principal investigator 1 Corcept Therapeutics $842.40 03/16/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568763
Principal investigator 1 Corcept Therapeutics $4,901.40 03/06/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568725
Principal investigator 1 Sage Therapeutics, Inc. $4,527.90 02/27/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749042025
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $324.05 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801585
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $101.32 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801589
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801593
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 02/22/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801597
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $565.77 02/21/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801573
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $101.32 02/21/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801577
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $120.00 02/21/2020 Covered Recipient Physician BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD No dispute reported 06/30/2026 748801581
Principal investigator 1 Alkermes, Inc. $85.00 02/14/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171959
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $55,422.89 02/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 748803947
Principal investigator 1 Sage Therapeutics, Inc. $180.00 02/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041757
Principal investigator 1 Sage Therapeutics, Inc. $60.00 02/13/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041763
Principal investigator 1 ACADIA Pharmaceuticals Inc $268.75 01/22/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381229
Principal investigator 1 ACADIA Pharmaceuticals Inc $50.00 01/22/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381239
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/22/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381245
Principal investigator 1 ACADIA Pharmaceuticals Inc $187.50 01/22/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381251
Principal investigator 1 ACADIA Pharmaceuticals Inc $62.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380843
Principal investigator 1 ACADIA Pharmaceuticals Inc $43.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380845
Principal investigator 1 ACADIA Pharmaceuticals Inc $81.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380847
Principal investigator 1 ACADIA Pharmaceuticals Inc $81.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380851
Principal investigator 1 ACADIA Pharmaceuticals Inc $68.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380855
Principal investigator 1 ACADIA Pharmaceuticals Inc $68.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380857
Principal investigator 1 ACADIA Pharmaceuticals Inc $68.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380861
Principal investigator 1 ACADIA Pharmaceuticals Inc $116.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380863
Principal investigator 1 ACADIA Pharmaceuticals Inc $62.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380867
Principal investigator 1 ACADIA Pharmaceuticals Inc $62.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380871
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380873
Principal investigator 1 ACADIA Pharmaceuticals Inc $62.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380877
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380879
Principal investigator 1 ACADIA Pharmaceuticals Inc $50.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380883
Principal investigator 1 ACADIA Pharmaceuticals Inc $50.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380887
Principal investigator 1 ACADIA Pharmaceuticals Inc $62.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380889
Principal investigator 1 ACADIA Pharmaceuticals Inc $281.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380893
Principal investigator 1 ACADIA Pharmaceuticals Inc $250.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380895
Principal investigator 1 ACADIA Pharmaceuticals Inc $250.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380899
Principal investigator 1 ACADIA Pharmaceuticals Inc $268.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380901
Principal investigator 1 ACADIA Pharmaceuticals Inc $250.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380905
Principal investigator 1 ACADIA Pharmaceuticals Inc $250.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380908
Principal investigator 1 ACADIA Pharmaceuticals Inc $81.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380911
Principal investigator 1 ACADIA Pharmaceuticals Inc $281.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380915
Principal investigator 1 ACADIA Pharmaceuticals Inc $43.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380917
Principal investigator 1 ACADIA Pharmaceuticals Inc $356.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380921
Principal investigator 1 ACADIA Pharmaceuticals Inc $356.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380925
Principal investigator 1 ACADIA Pharmaceuticals Inc $356.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380927
Principal investigator 1 ACADIA Pharmaceuticals Inc $206.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380931
Principal investigator 1 ACADIA Pharmaceuticals Inc $106.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380933
Principal investigator 1 ACADIA Pharmaceuticals Inc $281.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380937
Principal investigator 1 ACADIA Pharmaceuticals Inc $268.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380939
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380941
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380945
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380947
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380951
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380955
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380959
Principal investigator 1 ACADIA Pharmaceuticals Inc $106.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380961
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380965
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380967
Principal investigator 1 ACADIA Pharmaceuticals Inc $106.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380971
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380975
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380977
Principal investigator 1 ACADIA Pharmaceuticals Inc $187.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380981
Principal investigator 1 ACADIA Pharmaceuticals Inc $43.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380985
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380987
Principal investigator 1 ACADIA Pharmaceuticals Inc $62.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380991
Principal investigator 1 ACADIA Pharmaceuticals Inc $93.75 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380993
Principal investigator 1 ACADIA Pharmaceuticals Inc $206.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380997
Principal investigator 1 ACADIA Pharmaceuticals Inc $187.50 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748380999
Principal investigator 1 ACADIA Pharmaceuticals Inc $250.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381003
Principal investigator 1 ACADIA Pharmaceuticals Inc $156.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381005
Principal investigator 1 ACADIA Pharmaceuticals Inc $156.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381007
Principal investigator 1 ACADIA Pharmaceuticals Inc $156.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381009
Principal investigator 1 ACADIA Pharmaceuticals Inc $116.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381013
Principal investigator 1 ACADIA Pharmaceuticals Inc $116.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381017
Principal investigator 1 ACADIA Pharmaceuticals Inc $206.25 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381019
Principal investigator 1 ACADIA Pharmaceuticals Inc $250.00 01/15/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
ACP-103-034 No dispute reported 06/30/2026 748381021
Principal investigator 1 Alkermes, Inc. $85.00 01/14/2020 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724171955
Principal investigator 1 Sage Therapeutics, Inc. $6,275.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041103
Principal investigator 1 Sage Therapeutics, Inc. $750.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041105
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041107
Principal investigator 1 Sage Therapeutics, Inc. $3,000.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041109
Principal investigator 1 Sage Therapeutics, Inc. $1,000.00 01/09/2020 Non-covered Recipient Entity
PILLAR CLINICAL RESEARCH LLC
217-MDD-302 No dispute reported 06/30/2026 749041111
Principal investigator 1 Corcept Therapeutics $3,000.00 01/08/2020 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 745568721
Principal investigator 1 Biogen, Inc. $131,637.40 01/02/2020 Non-covered Recipient Entity
Pillar Clinical Research
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) No dispute reported 06/30/2026 736754749